Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- Product Overview:
PTEN-induced putative kinase 1 (PINK1) is a serine/threonine protein kinase that has a role in mitochondrial function.{54198,54199} It is comprised of an N-terminal mitochondrial targeting sequence, a transmembrane domain, a serine/threonine kinase domain, and a C-terminal region.{54199} PINK1 is ubiquitously expressed primarily in the brain, skeletal muscle, and heart.{54200} It localizes to the mitochondria where it is either rapidly degraded or, under conditions of low mitochondrial membrane potential, accumulates on the outer mitochondrial membrane, where it recruits and activates the cytosolic E3 ubiquitin ligase Parkin, which targets the mitochondria for mitophagy.{54200,54198} Pink1 knockout in rats leads to an age-dependent loss of dopaminergic neurons in the substantia nigra, as well as deficits in motor function and mitochondrial respiration.{54201} In mice, Pink1 knockout does not induce a loss of dopaminergic neurons without concomitant overexpression of ?-synuclein in the substantia nigra.{54202} Loss-of-function mutations in PINK1 are causally associated with autosomal recessive early-onset Parkinson’s disease.{54200,12321} Cayman’s PINK1 Polyclonal Antibody can be used for immunohistochemistry (IHC) and Western blot (WB) applications. The antibody primarily recognizes full-length PINK1 at approximately 66 kDa from human, mouse, and rat samples but also detects a truncated form of the protein at approximately 33 kDa.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.